Pharmacotherapy and Intensive Treatment - 2

This study has been completed.

Sponsors and Collaborators:	National Institute on Drug Abuse (NIDA) Department of Veterans Affairs
Information provided by:	National Institute on Drug Abuse (NIDA)
ClinicalTrials.gov Identifier:	NCT00000218

Purpose

The purpose of this study is to evaluate desipramine and carbamazepine in reducing cocaine craving; increase outpatient treatment capacity and evaluate their incidence of psychiatric disorders.

Condition	Intervention	Phase
Cocaine-Related Disorders Substance-Related Disorders	Drug: Carbamazepine	Phase IV

Drug Information available for: Carbamazepine

U.S. FDA Resources

Study Type:	Interventional
Study Design:	Treatment
Official Title:	Pharmacotherapy and Intensive Treatment

Further study details as provided by National Institute on Drug Abuse (NIDA):

Primary Outcome Measures:

Severity addiction
Depression
Depression, anxiety

Estimated Enrollment:

353

Eligibility

Ages Eligible for Study:	18 Years to 60 Years
Genders Eligible for Study:	Female
Accepts Healthy Volunteers:	No

Criteria

Please contact site for information.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00000218

Locations

United States, Missouri
University of Kansas
Kansas City, Missouri, United States, 64128

Sponsors and Collaborators

National Institute on Drug Abuse (NIDA)

Department of Veterans Affairs

Investigators

Principal Investigator:

William Haning, M.D.

University of Kansas

More Information

Study ID Numbers:	NIDA-06954-2, R18-06954-2
Study First Received:	September 20, 1999
Last Updated:	January 2, 2009
ClinicalTrials.gov Identifier:	NCT00000218
Health Authority:	United States: Federal Government

Study placed in the following topic categories:

Cocaine-Related Disorders
Carbamazepine
Mental Disorders
Substance-Related Disorders
Disorders of Environmental Origin

Additional relevant MeSH terms:

Disease
Tranquilizing Agents
Physiological Effects of Drugs
Psychotropic Drugs
Central Nervous System Depressants
Antimanic Agents
Pharmacologic Actions
Pathologic Processes

Analgesics, Non-Narcotic
Sensory System Agents
Therapeutic Uses
Analgesics
Peripheral Nervous System Agents
Central Nervous System Agents
Anticonvulsants

ClinicalTrials.gov processed this record on January 15, 2009